Atrophic gastritis should be reviewed regularly and should follow the principle of individualization, with a monitoring program developed by the physician according to the extent of the patient’s lesions combined with specific circumstances. It is recommended that: (1) patients with mild heterogeneous hyperplasia, age >60 years or (and) with severe atrophic gastritis should be followed up at intervals of six months, while mild heterogeneous hyperplasia in other cases may be followed up for one year; (2) moderate heterogeneous hyperplasia has a high cancer rate and should be followed up every three months in the first year after diagnosis, which may be extended to six months thereafter; (3) severe heterogeneous hyperplasia has the highest cancer rate and should be immediately reviewed by gastroscopy and pathology (3) Severe heterogeneous hyperplasia has the highest rate of cancer and should be immediately reviewed by gastroscopy and pathology, and if necessary, mucosal resection or surgery should be performed.